On January 31, 2023 BeiGene, Ltd. (the "Company") reported that it has entered into a Share Purchase Agreement dated October 31, 2019, as amended, by and between the Company and Amgen Inc. ("Amgen") pursuant to which, among other things, (i) the Company issued 206,635,013 ordinary shares in the form of 15,895,001 American Depositary Shares ("ADSs"), to Amgen for aggregate gross proceeds of approximately $2.78 billion, and (ii) subject to certain qualifications, the Company granted Amgen the right to appoint a designated director to the Company’s board of directors (such agreement, the "Share Purchase Agreement") (Filing, 8-K, BeiGene, JAN 31, 2023, View Source [SID1234626671]). On January 30, 2023, on account of the Company’s global growth, Amgen elected to relinquish its right to appoint a designated director to the Company’s board of directors, pursuant to an Amendment No. 3 to the Share Purchase Agreement (the "Amendment"). The Company will retain Anthony C. Hooper, who was Amgen’s director designee on the Company’s board of directors until Amgen relinquished its right to appoint a designated director. Mr. Hooper was most recently re-elected by shareholders in 2022 to serve a three-year term ending 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The foregoing description of the terms of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement, which the Company intends to file as an exhibit to a subsequent periodic report or on an amendment to this Current Report on Form 8-K.